Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

NCT03482752 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
60
Enrollment
INDUSTRY
Sponsor class

Stopped SAV006-03 was initiated before the evaluation of the IMPALA study (NCT02702180) results. Considering these results and authority advice there would not be adequate efficacy and safety data from SAV006-03 and the study was terminated.

Conditions

Interventions

Sponsor

Savara Inc.